Cost-effectiveness evaluation of pioglitazone versus metformin and glibenclamide in the treatment of type 2 diabetes mellitus outpatients in the national institute “salvador subir

• In: Posters: Social and Administrative Pharmacy Section
• At: Bangkok (Thailand) (2014)
• Type: Poster
• Poster code: POSSAPS002
• By: ALTAGRACIA-MARTíNEZ, Marina (Metropolitan Autonomous University Campus Xochimilco, Biological Systems, Mexico, Mexico)
• Co-author(s): Cruz-Hernández, Carlos David (Metropolitan Autonomous University Campus Xochimilco, Mexico, Mexico)
  González-García, Samuel (Metropolitan Autonomous University Campus Xochimilco, Mexico, Mexico)
  Machorro-Rojas, Nancy (Metropolitan Autonomous University Campus Xochimilco, Mexico, Mexico)
  Sánchez-Hernández, Gisela Monserrat (Metropolitan Autonomous University Campus Xochimilco, Mexico, Mexico)
  Kravzov-Jinich, Jaime (Metropolitan Autonomous University Campus Xochimilco, Mexico, Mexico)
  
• Abstract:

  Introduction: In Mexico, type 2 diabetes mellitus (DM-2) is one of the leading causes of death.
  Aims: To evaluate the cost-effectiveness ratios of the pioglitazone, metformin and glibenclamide used in the treatment of outpatients with DM-2.
  Methods: Twenty-seven adult outpatients with DM-2 who were treated either with pioglitazone or metformin or..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login